PAI-1 activity, but not fibrinogen or von Willebrand factor, is inversely retated to LDL particte size in type 2 diabetes

被引:6
|
作者
Mertens, Ilse [1 ]
Lemieux, Isabelle [2 ]
Verrijken, An [1 ]
Despres, Jean-Pierre [2 ]
Van Gaal, Luc F. [1 ]
机构
[1] Univ Antwerp Hosp, Fac Med, Dept Diabetol Metab & Clin Nutr, B-2650 Antwerp, Belgium
[2] Laval Hosp Res Ctr, Quebec Heart Inst, Ste Foy, PQ, Canada
关键词
fibrinogen; von Willebrand factor; plasminogen activator inhibitor-1; small LDL; visceral adiposity;
D O I
10.1002/dmrr.779
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Levels of fibrinogen, von Willebrand factor (vWF) and plasminogen activator inhibitor-1 (PAI-1) have been associated with small low-density lipoprotein (LDL) particles. However, it is not clear whether these associations are independent of visceral adiposity or other components of the metabolic syndrome such as triglycerides or insulin resistance. Methods Visceral adipose tissue (VAT; CT-scan), fibrinogen, von Willebrand factor antigen (vWF: Ag), PAI-1 activity and different metabolic parameters such as total cholesterol (chol), HDL-chol, triglycerides, insulin resistance (homeostasis model assessment; HOMA-IR) were determined in 41 women and 78 men with type 2 diabetes. LDL particle size was assessed by polyacrylamide gradient gel electrophoresis. Results PAI-1 activity was inversely related to LDL particle size after adjustment for age and body mass index (BMI) (r = -0.28; p = 0.006) or age and VAT (r = -0.26; p = 0.01), but not after adjustment for age and HOMA-IR (r = -0.15; p = 0.148) or age and triglycerides (r = -0.04; p = 0.679). in multiple regression analysis, LDL particle size did not independently determine PAI-1 activity levels. Fibrinogen and vWF: Ag did not seem to be related to LDL size. Conclusions PAI-1 activity levels, in contrast to fibrinogen and vWF:Ag, seem to be related to the small LDL phenotype in patients with type 2 diabetes. However, this relationship was not independent of insulin resistance or triglycerides. Copyright (c) 2007 John Wiley & Sons, Ltd.
引用
收藏
页码:141 / 147
页数:7
相关论文
共 39 条
  • [1] The additive effect of type 2 diabetes on fibrinogen, von Willebrand factor, tryptophan and threonine in people living with HIV
    Michelle L. Harrison
    Anthony S. Wolfe
    Jonathan Fordyce
    Jamie Rock
    Alexandra A. García
    Julie A. Zuñiga
    Amino Acids, 2019, 51 : 783 - 793
  • [2] The additive effect of type 2 diabetes on fibrinogen, von Willebrand factor, tryptophan and threonine in people living with HIV
    Harrison, Michelle L.
    Wolfe, Anthony S.
    Fordyce, Jonathan
    Rock, Jamie
    Garcia, Alexandra A.
    Zuniga, Julie A.
    AMINO ACIDS, 2019, 51 (05) : 783 - 793
  • [3] Changes in von Willebrand factor level and von Willebrand activity with age in type 1 von Willebrand disease
    Rydz, N.
    Grabell, J.
    Lillicrap, D.
    James, P. D.
    HAEMOPHILIA, 2015, 21 (05) : 636 - 641
  • [4] Severity of venous insufficiency is related to the density of microvascular deposition of PAI-1, uPA and von Willebrand factor
    Kolbach, DN
    Hamulyák, K
    Prins, MH
    Neumann, HAM
    Cleutjens, JPM
    VASA-JOURNAL OF VASCULAR DISEASES, 2004, 33 (01): : 19 - 24
  • [5] Effects of carvedilol or metoprolol on PAI-1, tPA-mass concentration or Von Willebrand factor in chronic heart failure - a COMET substudy
    Boman, Kurt
    Jansson, Jan-Hakan
    Nilsson, Torbjorn
    Swedberg, Karl
    Cleland, John G. F.
    Poole-Wilson, Philip
    THROMBOSIS RESEARCH, 2010, 125 (02) : E46 - E50
  • [6] Von Willebrand Factor (VWF) multiplex activity assay differentiation of type 1 von Willebrand Disease (VWD) and variant VWD
    Roberts, Jonathan C.
    Christopherson, Pamela A.
    Tarantino, Michael D.
    Gonzales, Sarah E.
    Morateck, Patti A.
    Perry, Crystal L.
    Flood, Veronica H.
    Abshire, Thomas C.
    Montgomery, Robert R.
    HAEMOPHILIA, 2024, 30 (01) : 161 - 168
  • [7] Association of Pigment Epithelium Derived Factor With von Willebrand Factor and Plasminogen Activator Inhibitor 1 in Patients With Type 2 Diabetes
    Karasek, D.
    Spurna, J.
    Kubickova, V
    Krystynik, O.
    Cibickova, L.
    Schovanek, J.
    Goldmannova, D.
    PHYSIOLOGICAL RESEARCH, 2019, 68 (03) : 409 - 418
  • [8] Elevated plasma factor VIII and von Willebrand factor in women with type 2 diabetes: inflammatory reaction, endothelial perturbation or else?
    Soares, Anna L.
    Kazmi, Rashid S.
    Borges, Michelle A.
    Rosario, Pedro W.
    Fernandes, Ana P.
    Sousa, Marinez O.
    Lwaleed, Bashir A.
    Carvalho, Maria G.
    BLOOD COAGULATION & FIBRINOLYSIS, 2011, 22 (07) : 600 - 605
  • [9] Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: Diagnostic and therapeutic implications
    Michiels, JJ
    van de Velde, A
    van Vliet, HHDM
    van der Planken, M
    Schroyens, W
    Berneman, Z
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2002, 28 (02) : 111 - 131
  • [10] Inverse relationship between plasma von Willebrand factor and soluble P selectin in patients with type 1 but not type 2 von Willebrand disease
    Blann, AD
    Nitu-Whalley, IC
    Lee, CA
    Lip, GYH
    AMERICAN JOURNAL OF HEMATOLOGY, 2002, 69 (02) : 135 - 137